,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['paradigm', 'breast', 'enhertu']
enhertu benefit in her2-low breast cancer wows at #asco22; signals shifting therapy, dx paradigms 
Journalist: Personalized medicine, genomics, cancer; Managing editor: @PrecOncNews 
https://t.co/t2jQRuYQgf 
@GenomeWeb 
https://t.co/MOrpOLPAKt